Ocular Therapeutix(NASDAQ) OCUL

Ocular Therapeutix, Inc. helps people recover from eye surgery. The company makes soft gels that deliver medicine over long periods. This helps patients avoid using daily eye drops.

What's in the Medicine Cabinet?

• DEXTENZA: Ophthalmic insert that treats eye pain and itching after surgery; generated all net product revenue in the three-month period ended June 30, 2026.
• ReSure Sealant: Liquid bandage used to prevent fluid leaks from the eye after cataract surgery.
• AXPAXLI: Investigational gel injected into the eye to treat wet age-related macular degeneration (a condition causing vision loss from aging).
• OTX-TIC: Long-acting implant in testing to reduce eye pressure for patients with glaucoma or ocular hypertension.

Scaling Up the Pipeline

• Announced positive topline results for the SOL-1 Phase 3 trial in Feb. 2026, showing AXPAXLI helped patients maintain vision for 52 weeks.
• Plans to submit a new drug application (NDA) for marketing approval of AXPAXLI in the fourth quarter of 2026.
• Completed the randomization of 640 subjects for the SOL-R clinical trial to evaluate repeat dosing of AXPAXLI.
• Partnered with AffaMed Therapeutics Limited to develop and sell DEXTENZA and OTX-TIC in specific international markets.

The Science of Sustained Release

The company uses its proprietary ELUTYX technology to create hydrogels (a gel that the body can naturally dissolve). This system delivers medicine consistently for several months to help patients who struggle with daily eye drop schedules.

A Look at the Financials

• Net product revenue was $13.5 million for the three-month period ended June 30, 2026, up 0.7% year over year.
• Research and development expenses were $120.4 million for the six-month period ended June 30, 2026, up $26.5 million year over year.
• Interest income reached $11.5 million for the six-month period ended June 30, 2026, up $4.2 million year over year.
• Cash and cash equivalents totaled $598.6 million as of June 30, 2026.
• Market cap was $2.2 billion in the second quarter of 2026, up 37.7% year over year.

Bottom Line

Ocular Therapeutix has moved from a specialty surgical product company to a late-stage clinical developer focused on major retinal diseases. Its hydrogel platform serves as the foundation for a pipeline that seeks to simplify complex treatment schedules for eye patients.